ETS1 inactivation causes innate drug resistance to EGFR inhibitors.
Mutations in epidermal growth factor receptor (EGFR) are found in approximately 10% of lung cancers. Treatment with EGFR inhibitors, although promising, has surprisingly resulted in greater than 90% tumor reduction in only 5% of cases, prompting us to investigate the mechanism of innate drug resistance.
Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of California, San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California, San Francisco, CA, USA.
Osamu
O
Tetsu
Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of California, San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California, San Francisco, CA, USA.
Janyaporn
J
Phuchareon
Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of California, San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California, San Francisco, CA, USA.
David W
DW
Eisele
UCSF Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California , San Francisco, CA, USA.
Frank
F
McCormick
BCL2L11 (best known as BIM); ETS1 transcription factor; MAPK1 (best known as ERK2); MAPK3 (best known as ERK1); dual specificity phosphatase 6 (DUSP6); epidermal growth factor receptor (EGFR); innate drug resistance; non-small-cell lung cancer (NSCLC); tyrosine kinase inhibitor (TKI)